ArticleRevista da Associacao Medica Brasileira (1992)2026
Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of TP53 mutations in metastatic colorectal cancer remains unclear owing to inconsistent findings in the literature. Given its central role in tumor biology, clarifying the impact of TP53 status on survival outcomes is clinically relevant.
methodsThis retrospective cohort study included 115 patients with metastatic colorectal cancer who underwent TP53 mutational analysis using next-generation sequencing (KAPA HyperPETE Pan Cancer Panel). Eligible patients were aged ≥18 years, had histologically confirmed metastatic colorectal cancer, and received first-line systemic therapy. Patients with incomplete clinical or molecular data were excluded. Based on mutation profiles, those with RAS or BRAF mutations received anti-VEGF therapy, whereas patients with wild-type tumors received anti-EGFR treatment. Patients were stratified according to TP53 mutation status to evaluate differences in clinical outcomes.
resultsAmong the 115 patients included, 78 (67.8%) harbored TP53 mutations and 37 (32.2%) had wild-type TP53. The median progression-free survival was significantly longer in the TP53-mutant group (18.6 vs. 10.0 months; p=0.002). The median overall survival was also numerically longer in the TP53-mutant group (32.9 vs. 30.3 months), although this difference was not statistically significant (p=0.114). In the univariate analysis, TP53 mutation was associated with improved progression-free survival (HR 0.479; 95%CI 0.294-0.779; p=0.003). This association remained independently significant in the multivariate analysis (HR 0.477; 95%CI 0.289-0.787; p=0.004). None of the other variables consistently predicted survival.
conclusionTP53 mutations appear to be an independent prognostic marker for prolonged progression-free survival in patients with metastatic colorectal cancer. Although the difference in overall survival was not statistically significant, these findings warrant further validation in prospective studies to confirm the prognostic utility of TP53 in therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.